Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.17Last Year’s EPS
-0.06Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 5.15%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant financial growth and strategic advancements in product development and international market expansion. Despite minor concerns about potential tariffs and decisions regarding development expenses with Lilly, Rigel's overall performance and outlook remain strong.Company Guidance
During the first quarter of 2025, Rigel Pharmaceuticals reported robust year-over-year growth, with net product sales increasing by 68% to $43.6 million. The growth was driven by the addition of GAVRETO to their portfolio, as well as continued momentum in sales of TAVALISSE and REZLIDHIA. TAVALISSE alone contributed $28.5 million in net product sales, reflecting a 35% increase compared to the same period in 2024. The total revenue for the quarter reached $53.3 million, including $9.8 million from collaborations. Notably, Rigel achieved a net income of $11.4 million during a time when the business environment is challenging for the biotech sector. The company maintained its guidance for 2025, expecting total revenue between $200 million and $210 million and a positive net income for the full year. Additionally, Rigel highlighted the progress in their development pipeline, including R289, a dual IRAK1 and 4 inhibitor, and plans to expand olutasidenib into a Phase II study for recurrent glioma.Significant Revenue Growth
Rigel Pharmaceuticals reported a 68% year-over-year net product sales growth, with total revenue of $53.3 million for the quarter.
Positive Financial Performance
Generated $11.4 million in net income for the quarter, demonstrating a profitable start to the fiscal year.
Expansion of Product Portfolio
The commercial portfolio now includes three products: TAVALISSE, GAVRETO, and REZLIDHIA, with each showing significant sales growth.
Successful International Expansion
TAVALISSE is now commercially available in several international markets, including Japan, Europe, Canada, Israel, and Mexico.
Advancement in Development Pipeline
Progress in the clinical development of R289 and olutasidenib, with plans for a Phase II study in recurrent glioma.
Strategic Collaborations
Partnerships with MD Anderson and CONNECT to advance the potential of olutasidenib in multiple indications.
RIGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RIGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $18.26 | $18.47 | +1.15% |
Mar 04, 2025 | $22.08 | $20.29 | -8.11% |
Nov 07, 2024 | $15.44 | $22.07 | +42.94% |
Aug 06, 2024 | $9.33 | $9.87 | +5.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rigel (RIGL) report earnings?
Rigel (RIGL) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Rigel (RIGL) earnings time?
Rigel (RIGL) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RIGL EPS forecast?
RIGL EPS forecast for the fiscal quarter 2025 (Q2) is 1.17.